How Medical Prior Authorization Delays Are Directly Harming Patient Outcomes
Medical Prior Authorization, the process insurers use to approve treatments before they are covered, has become one of the most debated friction points in American healthcare. And the debate is not really about whether the process should exist. It is about what happens in the time between a clinician ordering care and an insurer signing off on it. That gap is not neutral. It has a clinical cost, and in many cases, that cost is paid by the patient.
This article looks at where delays actually occur, what they do to patient outcomes, and what can realistically be done about it across patients, practices, and payers.
What Prior Authorization Actually Is (And How It Works in Practice)
Prior authorization (PA) is a requirement that a clinician or facility obtain insurer approval before certain medications, procedures, imaging studies, or specialist visits will be covered. The intended logic is that it filters out low-value or unnecessary care and controls spending.
The workflow typically looks like this: a clinician places an order, the system flags that PA is required, staff submit documentation to the insurer, the insurer reviews it and either approves, denies, or requests additional information. If additional information is requested, the clock effectively resets. If denied, an appeal can be filed. That appeal may go through reconsideration, an internal review, or an external independent review, in that order.
PA is distinct from related terms that often get conflated. Precertification refers specifically to pre-approval for planned procedures. Step therapy requires patients to try and fail on a less expensive medication before the preferred one is approved. Formulary restrictions simply limit which drugs are covered at all.
The stated rationale from payers is cost control and clinical safety. The practical tradeoff is access delay, and when care is time-sensitive, that tradeoff is not abstract.
The 7 Bottlenecks That Actually Slow Things Down
Understanding where delays accumulate is the first step to addressing them. There are seven recognizable choke points in the typical PA process.
The first is unclear or shifting payer criteria. Documentation requirements are not always published, and they vary by plan, by drug, and sometimes by the reviewer. A submission that would have been approved last month may be denied today because the insurer quietly updated its policy.
The second is administrative back-and-forth. Missing a single diagnosis code, submitting the wrong form version, or attaching the wrong clinical note is enough to trigger a rejection that requires starting over.
The third is payer response time windows. Standard PA timelines can extend to 72 hours or longer. When a payer sends a request for more information, the internal clock often resets entirely. A one-week process can stretch into two.
The fourth is peer-to-peer scheduling. When a clinician needs to speak directly with a payer’s medical reviewer, that call does not happen the same day. Coordinating schedules across organizations often adds several days, if not more.
The fifth is the multi-layer appeals process. Even when a denial is wrong, reversing it requires going through reconsideration, then internal appeal, then potentially external review. Each step takes time that the patient does not always have.
The sixth is specialty pharmacy logistics. Even after a medication is approved, it still needs to go through benefit investigation, prior authorization at the pharmacy level, and shipping. A three-day clinical delay can become a 10-day total delay by the time the medication arrives.
The seventh is re-authorization for ongoing therapies. Patients on stable chronic medications or biologics frequently have to re-qualify mid-treatment. If re-authorization is delayed, therapy is interrupted even though the clinical case has not changed.
How Delays Translate Into Worse Outcomes
There are six reasonably direct pathways from a PA delay to clinical harm.
The first is disease progression. When a patient is waiting for approval, their condition does not pause. Inflammatory conditions flare. Tumors progress. Infections advance. Every day without treatment is a day the disease is running without resistance.
The second is missed diagnostic windows. A delayed MRI or lab panel can push a diagnosis into a later and less treatable stage. The decision to image was made at the right time. The image just never happened when it should have.
The third is therapy interruption. Stopping and restarting a medication is not the same as never starting it. For some treatments, consistency is the mechanism of action. Interruptions reduce efficacy and, in some cases like certain psychiatric or antiretroviral medications, increase resistance risk.
The fourth is substitution with inferior options. Step therapy forces patients onto less effective treatments first. A patient who needs a biologic ends up on an NSAID. A patient who cannot tolerate a first-line medication must fail it formally before a better option is approved.
The fifth is avoidable emergency department visits and hospitalizations. When outpatient care is blocked, conditions escalate. A patient who could not get a covered infusion appointment ends up in the ED. That visit is more expensive, more traumatic, and more resource-intensive than the outpatient care that was delayed.
The sixth is treatment abandonment. Many patients simply stop pursuing care when the approval process becomes overwhelming. The complexity, the phone calls, the re-submissions, and the uncertainty are enough to cause some patients to give up entirely.
What the Evidence Shows
The professional and research consensus on this is consistent. The American Medical Association has surveyed physicians annually on PA and found, year after year, that the majority report that PA has caused delays in care, and a significant portion report it has led to serious adverse events for their patients.
Studies tracking overturned denials are particularly telling. When PA denials are appealed and reversed, it means the original denial was incorrect. But the reversal does not undo the delay. A patient whose approval was held for three weeks while an appeal worked its way through review still waited three weeks. The clinical damage from that window is not recovered just because the final answer was yes.
CMS audits of Medicare Advantage plans have found cases where prior authorization was used to deny care that met coverage criteria. GAO reports have documented widespread inconsistency in how criteria are applied across plans and geographic regions.
The pattern is consistent enough that most major specialty societies including oncology, cardiology, rheumatology, and psychiatry organizations have published formal position statements calling for PA reform.
Who Gets Hit Hardest
The burden of PA delays is not evenly distributed. Some patients are hit far harder than others.
Patients with complex chronic conditions face more PA touchpoints. Someone managing an autoimmune condition with a biologic, a comorbid mood disorder, and recurring imaging requirements may encounter PA requirements multiple times per month across different services and payers.
Cancer and autoimmune patients on specialty drugs face some of the highest denial rates and longest review timelines. For these patients, delays measured in weeks can change how a disease responds to treatment.
Mental health patients are particularly vulnerable to therapy interruptions. A forced medication switch due to step therapy, or a re-authorization delay, can cause a relapse that disrupts employment, housing stability, and family relationships.
Pediatric and rare disease patients often have no alternative options. Denying or delaying the one approved therapy for a rare condition is functionally a denial of all treatment.
Rural and underserved patients are least equipped to absorb delays. Smaller clinic staff means fewer people available to navigate appeals. Limited specialty access means that if a referral is delayed, there is no nearby substitute. Language barriers, low health literacy, and unstable phone access all make the appeals process harder to complete.
The table below summarizes how the harm profile differs across patient populations.
| Patient Group | Primary PA Risk | Why Delays Hit Harder |
|---|---|---|
| Complex chronic conditions | Multiple simultaneous PA requirements | More touchpoints, more chances for delay or interruption |
| Cancer / autoimmune disease | Specialty biologic and infusion denials | Delays can change disease trajectory and treatment response |
| Mental health | Forced medication switches via step therapy | Abrupt changes can destabilize managed conditions |
| Pediatric / rare disease | No therapeutic alternatives | Denial of one therapy is effectively denial of all care |
| Rural and underserved patients | Limited staff and specialist access | Fewer resources to manage appeals; no nearby backup |
Why Expedited PA Is Not the Fix It Sounds Like
Most payers offer an expedited or urgent PA pathway. It sounds like a safety valve, but in practice it is narrowly defined and inconsistently applied.
Expedited review typically requires documentation that standard timelines would seriously jeopardize the patient’s health. Getting a payer to agree that a case meets that bar is itself a clinical argument that must be made in real time, often by phone, often by administrative staff rather than clinicians.
Even when expedited status is granted, review still takes 24 to 72 hours in many plans. Peer-to-peer calls do not always connect a clinician with another clinician. Scheduling those calls adds more time. After-hours and weekend coverage is often limited, so delays that begin on a Thursday can absorb a full weekend.
Well-run clinics with dedicated authorization staff still run into these barriers. They are structural, not operational.
The Ripple Effects on the Practice Itself
The harm from PA delays does not stay with the patient. It flows back through the practice in ways that ultimately reduce the quality of care available to everyone.
Clinicians and staff spend hours per week on PA-related tasks. That time is taken directly from patient visits, care coordination, and follow-up. As administrative burden grows, burnout accelerates and experienced staff leave.
Clinic workflows strain under the volume of PA submissions, portal logins, phone calls, and resubmissions. Appointment availability shrinks as staff capacity is absorbed by paperwork. Handoffs between the ordering clinician, the authorization team, the patient, and the pharmacy or imaging center become fragmented and error-prone.
And then there is the cost paradox: prior authorization was designed to reduce unnecessary spending, but when it delays necessary care, it often generates more downstream costs in the form of ED visits, hospitalizations, duplicate testing, and prolonged disease management.
What Patients Can Do to Reduce Their Own Risk
Patients are not powerless, but they need to take a more active role in the PA process than most realize.
The most effective thing a patient can do is ask the question early: “Will this need prior authorization?” at the time of prescribing or ordering. Getting a yes or no at that moment allows everyone to get ahead of the timeline.
Patients should also keep a documented summary of their treatment history, including medications tried, side effects experienced, and why alternatives did not work. This is the foundation of a medical necessity argument, and having it ready can accelerate the submission significantly.
If a PA is denied, patients have the right to the denial reason in writing and a clear explanation of the appeals steps. They should ask the clinician’s office whether a peer-to-peer review is planned and follow up on that explicitly.
For specialty medications, confirming the specialty pharmacy assignment and expected shipping timeline immediately after approval avoids a second wave of delays on the logistics side.
What Clinics and Health Systems Can Change
On the practice side, the highest-impact changes are structural.
Standardizing PA intake with payer-specific templates and documentation checklists means that the first submission is more likely to be complete, which reduces back-and-forth significantly. Integrating PA requirement flags into the ordering workflow, before the order is finalized, gives the clinical team a chance to account for timelines in the care plan.
Practices with high PA volume benefit from centralized authorization teams or revenue cycle specialists. These roles develop payer-specific expertise that generalist staff cannot build across dozens of different insurers.
Tracking denial reasons and appeal success rates over time reveals patterns. If a specific payer is denying a particular medication category at high rates, that is information the practice can act on proactively. Scheduling blocks for peer-to-peer calls, maintaining direct escalation contacts at payers, and tightening handoffs between ordering clinicians and authorization staff all reduce the delay window meaningfully.
What Payers and Policymakers Can Do
Reform at the payer and policy level is where systemic change is possible.
Gold-carding programs, which exempt high-performing providers from PA requirements for specific care categories, reduce administrative burden without removing oversight from high-risk areas. Electronic prior authorization standards, when implemented properly, eliminate fax-based workflows and allow real-time status tracking.
Mandatory response time standards with hard deadlines, limits on clock resets after information requests, and restrictions on re-authorization frequency for stable therapies would reduce the most avoidable delays. Publishing PA criteria publicly and prohibiting undisclosed documentation requirements would reduce the guessing game that wastes time on both sides.
None of this requires eliminating PA entirely. The goal is to target review toward genuinely uncertain clinical situations while protecting timely access to care that is already evidence-based and time-sensitive.
The Core Point
Time is a clinical variable. Delays do not just inconvenience patients. They alter what treatments can accomplish, who gets to complete a course of therapy, and in some cases, whether a condition is managed or whether it becomes a crisis.
The most actionable thing any clinician or practice can do right now is look at the next service likely to require Medical Prior Authorization and get ahead of it. Ask early, document thoroughly, know the criteria, and build the follow-up cadence into the workflow from the start.
If your practice is still managing prior authorizations through manual processes and staff phone time, there is a better way. Notove is an AI-powered tool built specifically for small practices and clinics that drafts prior authorization letters, letters of medical necessity, and referral documentation in minutes. It is worth a look: notove.com
Frequently Asked Questions
What is medical prior authorization and why is it required?
Medical prior authorization is a requirement from a health insurer that a provider obtain approval before a covered service, medication, or procedure will be paid for. Insurers require it as a way to review whether a treatment meets their medical necessity criteria before committing to coverage. The practical effect is that care that a clinician has already decided is appropriate cannot proceed until the payer agrees.
How long does a typical prior authorization take to process?
Standard timelines vary by payer and service type, but most plans have up to 72 hours for standard reviews and 24 to 72 hours for expedited cases. In practice, incomplete submissions, requests for additional documentation, and peer-to-peer scheduling mean the real-world timeline is often longer. For specialty medications with pharmacy fulfillment steps, the end-to-end process from order to medication in hand can take one to two weeks.
Can a prior authorization denial actually be overturned?
Yes, and it happens frequently enough that the overturn rate is itself a data point about the quality of initial decisions. Denials can be challenged through reconsideration, internal appeal, and, if those fail, external independent review. The problem is that even a successful appeal does not undo the delay that occurred while the appeal was being processed.
What is step therapy and why does it matter for patient outcomes?
Step therapy is a PA requirement that patients try a less expensive or preferred drug before a more targeted therapy will be covered. Clinicians often identify step therapy protocols as a driver of harm because they require patients to fail on a treatment that may not be appropriate for their condition before the clinician’s actual recommendation is covered. That failure period can involve side effects, disease progression, or worsening symptoms.
What can a patient do if their prior authorization is taking too long?
Patients can ask the prescribing clinician’s office for a status update and confirm who is managing the submission. If the clinical situation is urgent, ask whether an expedited review request has been filed and what documentation was included. If the PA has been denied, request the denial in writing and ask about the specific appeal steps. Staying actively involved and following up regularly is more effective than waiting for the process to resolve on its own.
Why do prior authorization delays tend to hit smaller clinics harder?
Smaller practices have fewer staff and less dedicated administrative infrastructure. In a large hospital system, there may be an entire authorization department with payer-specific expertise. In a solo or small group practice, the same staff handling patient scheduling and billing are also managing PA submissions. That means less capacity for follow-up, fewer relationships with payer contacts, and less bandwidth to handle appeals on top of daily clinical operations.